Abstract: Provided herein is a heavy chain constant region comprising a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, wherein the sequences of said CH1 domain and hinge region derive from the sequences of CH1 domain and hinge region in human IgG2, the sequences of said CH2 domain and CH3 domain derive from the sequences of CH2 domain and CH3 domain in human IgGs; and wherein, said antibody heavy chain constant region has an affinity to human Fc?RIIB equal to or higher than the affinity of human IgG1 to human Fc?RIIB, said antibody heavy chain constant region has an I/A ratio equal to or higher than human IgG1 has. Also provided are antibodies or fusion proteins based on a heavy chain constant region according to the above, wherein the antibody heavy chain constant region significantly enhances agonistic activity of the antibodies or fusion proteins and improves efficacy of the antibodies or fusion proteins in treating diseases like tumors and autoimmune diseases.

Abstract: Provided are an anti-OX40 antibody, and a pharmaceutical composition and application thereof. The anti-OX40 antibody or an antigen-binding fragment and pharmaceutical composition thereof can be used for treating a T cell-related disease.

Abstract: Provided is a modified Fc region. The Fc region has at least one amino acid mutation with respect to a parent Fc region. The modified Fc region has improved affinity to Fc?RIIB with respect to the affinity of the parent Fc region to Fc?RIIB Also provided is an antibody containing the modified Fc region, especially an agonistic antibody. The modified Fc region has significant use for optimizing the agonistic activity of the antibody.

Abstract: Provided herein is a heavy chain constant region comprising a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, wherein the sequences of said CH1 domain and hinge region derive from the sequences of CH1 domain and hinge region in human IgG2, the sequences of said CH2 domain and CH3 domain derive from the sequences of CH2 domain and CH3 domain in human IgGs; and wherein, said antibody heavy chain constant region has an affinity to human Fc?RIIB equal to or higher than the affinity of human IgG1 to human Fc?RIIB, said antibody heavy chain constant region has an I/A ratio equal to or higher than human IgG1 has. Also provided are antibodies or fusion proteins based on a heavy chain constant region according to the above, wherein the antibody heavy chain constant region significantly enhances agonistic activity of the antibodies or fusion proteins and improves efficacy of the antibodies or fusion proteins in treating diseases like tumors and autoimmune diseases.

Abstract: An optical module and a method of transmitting data in the optical module are provided in the present disclosure. According to an example, the optical module may comprise a micro controller unit (MCU) and N number of first driving chips having a same chip address. The MCU may be configured with a serial data (SDA) bus interface and N number of first serial clock (SCL) bus interfaces. Each of the N number of first driving chips may be configured with a SDA bus interface which is configured to be connected with the SDA bus interface on the MCU and a SCL bus interface which is configured to be connected with one of the N number of first SCL bus interfaces on the MCU.

Abstract: An optical module and a method of transmitting data in the optical module are provided in the present disclosure. According to an example, the optical module may comprise a micro controller unit (MCU) and N number of first driving chips having a same chip address. The MCU may be configured with a serial data (SDA) bus interface and N number of first serial clock (SCL) bus interfaces. Each of the N number of first driving chips may be configured with a SDA bus interface which is configured to be connected with the SDA bus interface on the MCU and a SCL bus interface which is configured to be connected with one of the N number of first SCL bus interfaces on the MCU.

Abstract: The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.

Abstract: A greening roll includes water-temperature-light controlling part, root growing part, water/root regulating part and seed-stacking part which is located in the water-temperature-light controlling part. The water-temperature-light controlling part is located on the top surface of the greening roll, the water/root regulating part is located on the lower surface of the greening roll, the root growing part is located in the cavity composed by the water-temperature-light controlling part and the water/root regulating part, and the seed-stacking part is located in the cavity of the water-temperature-light controlling part. The water-temperature-light controlling part further includes top-located irradiation reflecting part, temperature-water regulating part, light-preventing part and seed-stacking cavity.

Abstract: A greening roll includes water-temperature-light controlling part, root growing part, water/root regulating part and seed-stacking part which is located in the water-temperature-light controlling part. The water-temperature-light controlling part is located on the top surface of the greening roll, the water/root regulating part is located on the lower surface of the greening roll, the root growing part is located in the cavity composed by the water-temperature-light controlling part and the water/root regulating part, and the seed-stacking part is located in the cavity of the water-temperature-light controlling part. The water-temperature-light controlling part further includes top-located irradiation reflecting part, temperature-water regulating part, light-preventing part and seed-stacking cavity.

Abstract: The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.